FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review

Stock News

02/13

FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1192481164"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192481164\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192481164?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192481164","market":"other","top_or_hot":-1,"title":"FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA's Cisplatin Injection Marketing Application Accepted for Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-13 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1192481164","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192481164","pubTimestamp":1770976456,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0060":"抗癌","BK0196":"行业龙头","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK1593":"医美概念股","BK1191":"制药","BK0096":"民营医院","BK0012":"证金概念","BK1515":"抗疫概念","BK0188":"融资融券","BK0175":"白马股"},"translate_title":"复星医药顺铂注射液上市申请获审评受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced that the marketing authorization application for Cisplatin Injection, submitted by its controlling subsidiary, Gismee (Wuhan) Pharmaceutical Co., Ltd., has been accepted by the National Medical Products Administration. This chemical drug, developed independently by the group, is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. As of January 2026, the group's cumulative R&D investment for this drug amounts to approximately RMB 4.69 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Cisplatin Injection in mainland China (excluding Hong Kong, Macao, and Taiwan regions) reached approximately RMB 165 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}